Optimal graft source for allogeneic hematopoietic stem cell transplant: Bone marrow or peripheral blood?

Janak Adhikari, Priyadarshani Sharma, Vijaya R Bhatt

Research output: Contribution to journalReview article

4 Scopus citations


Peripheral blood (PB), compared with bone marrow graft, has higher stem cell content, leads to faster engraftment and is more convenient for collection. Consequently, the use of PB graft has significantly increased in recent years. Although the use of PB graft is acceptable or even preferred to bone marrow graft in matched related donor allogeneic transplant due to a possibility of improved survival, PB graft increases the risk of chronic graft-versus-host disease and associated long-term toxicities in the setting of matched unrelated donor allogeneic transplant. In haploidentical transplant, mitigation of graft-versus-host disease with the use of post-transplant cyclophosphamide is a hypothesis-generating possibility; however, available studies have significant limitations to draw any definite conclusion.

Original languageEnglish (US)
Pages (from-to)1823-1832
Number of pages10
JournalFuture Oncology
Issue number15
Publication statusPublished - Aug 2016



  • allogeneic hematopoietic stem cell transplantation
  • graft source
  • graft-versus-host disease
  • survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this